UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Film of Type Responses)									, T			
1. Name and Address of Reporting Person [*] LAPOINTE ANTHONY GREGG	2. Issuer Name and RIGEL PHARM			· ·		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_Director10% Owner						
(Last) (First) RIGEL PHARMACEUTICALS, INC. VETERANS BLVD.	1100	3. Date of Earliest Tr 05/15/2020	ransaction (Montl	h/Day/Yea	ar)		Officer (give title below) Other (specify below)				
(Street) SOUTH SAN FRANCISCO, CA 9408		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)		Fable I - No	on-De	rivative S	Securitie	s Acqı	ired, Disposed of, or Beneficially Ow	ned			
(Instr. 3) D	. Transaction Date Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		4. Securi (A) or Di (Instr. 3, Amount	isposed o	f (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

-	(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4. 5. Number		6. Date Exercisable and		7. Title and Amount		8. Price of	9. Number of	10.	11. Nature		
Derivative	Conversion	Date	Execution Date, if	Transaction of Derivative		Expiration Date		of Underlying		Derivative	Derivative	Ownership	of Indirect		
		(Month/Day/Year)		Code	Code Securities				Securities		Security	Securities	Form of	Beneficial	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8					(Instr. 3 and 4)		· /	2	Derivative		
	Derivative				or Disposed							2	(Instr. 4)		
	Security			of (D)							0	Direct (D)			
				(Instr. 3, 4,								or Indirect			
				and 5)		-						Transaction(s) (Instr. 4)	(1) (Instr. 4)		
											Amount		(11150.4)	(11150.4)	
								Date	Expiration		or				
								Exercisable	Date		Number				
				Code	v	(A)	(D)				of Shares				
				Coue	v	(A)	(D)				Shares				
Stock															
Option	¢ 1 7(5	05/15/2020				55 000		(1)	05/15/2030	Common Stock	55 000	¢ 0	55,000	D	
(Right	\$ 1.765	05/15/2020		Α		55,000		<u></u>	05/15/2030	Stock	55,000	\$ 0	55,000	D	
to Buy)															
to Duy)															

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
LAPOINTE ANTHONY GREGG RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	Х						

Signatures

 /s/ Dolly Vance (Attorney-in-Fact)
 05/15/2020

 **Signature of Reporting Person
 Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.